Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 451 participants.
Also called NCT01517412
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 451 participants
- Sponsor
- Registry
-
NCT01517412 -
2011-002416-85
-
- Other papers using this trial's data
- Equal improvement in glycaemia with lixisenatide given before breakfast or the main meal of the day
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Czechia, France, Germany, Poland, Romania, Russia, Spain, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT01517412. Randomized; no masking; primary purpose treatment. Start 2012-02 (registry gives no type); primary completion 2013-05 (actual). Results posted on 2016-10-14.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparison of Lixisenatide Injected Prior to the Main Meal of the Day Versus Prior to Breakfast in Type 2 Diabetic Patients on Metformin
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Lixisenatide (AVE0010)
- Intervention (Device)
- Self-injector pen device (OptiClik®)
- Intervention (Drug)
- Metformin
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct01517412- Content hash
58b8f45ff8fde0207d04fd602cd487c937464f331051722dd05e99b0538f7ff4